170 related articles for article (PubMed ID: 34520129)
1. Proteomic profiling of extracellular vesicles and particles reveals the cellular response to cisplatin in NSCLC.
Xu J; Wang L; Yin N; Chen A; Yi J; Tang J; Xiang J
Thorac Cancer; 2021 Oct; 12(19):2601-2610. PubMed ID: 34520129
[TBL] [Abstract][Full Text] [Related]
2. Novel pathways involved in cisplatin resistance identified by a proteomics approach in non-small-cell lung cancer cells.
Milone MR; Lombardi R; Roca MS; Bruzzese F; Addi L; Pucci B; Budillon A
J Cell Physiol; 2019 Jun; 234(6):9077-9092. PubMed ID: 30362533
[TBL] [Abstract][Full Text] [Related]
3. Proteomics-based identification of secreted protein dihydrodiol dehydrogenase 2 as a potential biomarker for predicting cisplatin efficacy in advanced NSCLC patients.
Kuang P; Zhou C; Li X; Ren S; Li B; Wang Y; Li J; Tang L; Zhang J; Zhao Y
Lung Cancer; 2012 Aug; 77(2):427-32. PubMed ID: 22534668
[TBL] [Abstract][Full Text] [Related]
4. Proteome analysis of non-small cell lung cancer cell line secretomes and patient sputum reveals biofluid biomarker candidates for cisplatin response prediction.
Böttger F; Schaaij-Visser TB; de Reus I; Piersma SR; Pham TV; Nagel R; Brakenhoff RH; Thunnissen E; Smit EF; Jimenez CR
J Proteomics; 2019 Mar; 196():106-119. PubMed ID: 30710758
[TBL] [Abstract][Full Text] [Related]
5. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
Gao J; Meng Q; Zhao Y; Chen X; Cai L
BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
[TBL] [Abstract][Full Text] [Related]
6. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells.
Lu H; Xie X; Wang K; Chen Q; Cai S; Liu D; Luo J; Kong J
Mol Cell Biochem; 2020 Dec; 475(1-2):63-77. PubMed ID: 32767026
[TBL] [Abstract][Full Text] [Related]
7. FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells.
He Y; Xie H; Yu P; Jiang S; Wei L
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1049-1059. PubMed ID: 30302523
[TBL] [Abstract][Full Text] [Related]
8. Cell-cell contact-driven EphB1 cis- and trans- signalings regulate cancer stem cells enrichment after chemotherapy.
Wang L; Peng Q; Xie Y; Yin N; Xu J; Chen A; Yi J; Shi W; Tang J; Xiang J
Cell Death Dis; 2022 Nov; 13(11):980. PubMed ID: 36402751
[TBL] [Abstract][Full Text] [Related]
9. Protein Profiling of Extracellular Vesicles Associated With Cisplatin Resistance in Lung Cancer.
Balbinotti H; Cadore NA; Dutra CS; DA Silva ED; Ferreira HB; Zaha A; Monteiro KM
Anticancer Res; 2020 Oct; 40(10):5509-5516. PubMed ID: 32988874
[TBL] [Abstract][Full Text] [Related]
10. Profiling of apoptosis- and autophagy-associated molecules in human lung cancer A549 cells in response to cisplatin treatment using stable isotope labeling with amino acids in cell culture.
Wang Z; Liu G; Jiang J
Int J Oncol; 2019 Mar; 54(3):1071-1085. PubMed ID: 30664195
[TBL] [Abstract][Full Text] [Related]
11. Targeting NF-κB-mediated inflammatory pathways in cisplatin-resistant NSCLC.
Ryan SL; Beard S; Barr MP; Umezawa K; Heavey S; Godwin P; Gray SG; Cormican D; Finn SP; Gately KA; Davies AM; Thompson EW; Richard DJ; O'Byrne KJ; Adams MN; Baird AM
Lung Cancer; 2019 Sep; 135():217-227. PubMed ID: 31446998
[TBL] [Abstract][Full Text] [Related]
12. Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer.
Chen Y; Zhou H; Yang S; Su D
Cell Biochem Funct; 2021 Mar; 39(2):277-286. PubMed ID: 32815556
[TBL] [Abstract][Full Text] [Related]
13. Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.
Hoshino A; Kim HS; Bojmar L; Gyan KE; Cioffi M; Hernandez J; Zambirinis CP; Rodrigues G; Molina H; Heissel S; Mark MT; Steiner L; Benito-Martin A; Lucotti S; Di Giannatale A; Offer K; Nakajima M; Williams C; Nogués L; Pelissier Vatter FA; Hashimoto A; Davies AE; Freitas D; Kenific CM; Ararso Y; Buehring W; Lauritzen P; Ogitani Y; Sugiura K; Takahashi N; Alečković M; Bailey KA; Jolissant JS; Wang H; Harris A; Schaeffer LM; García-Santos G; Posner Z; Balachandran VP; Khakoo Y; Raju GP; Scherz A; Sagi I; Scherz-Shouval R; Yarden Y; Oren M; Malladi M; Petriccione M; De Braganca KC; Donzelli M; Fischer C; Vitolano S; Wright GP; Ganshaw L; Marrano M; Ahmed A; DeStefano J; Danzer E; Roehrl MHA; Lacayo NJ; Vincent TC; Weiser MR; Brady MS; Meyers PA; Wexler LH; Ambati SR; Chou AJ; Slotkin EK; Modak S; Roberts SS; Basu EM; Diolaiti D; Krantz BA; Cardoso F; Simpson AL; Berger M; Rudin CM; Simeone DM; Jain M; Ghajar CM; Batra SK; Stanger BZ; Bui J; Brown KA; Rajasekhar VK; Healey JH; de Sousa M; Kramer K; Sheth S; Baisch J; Pascual V; Heaton TE; La Quaglia MP; Pisapia DJ; Schwartz R; Zhang H; Liu Y; Shukla A; Blavier L; DeClerck YA; LaBarge M; Bissell MJ; Caffrey TC; Grandgenett PM; Hollingsworth MA; Bromberg J; Costa-Silva B; Peinado H; Kang Y; Garcia BA; O'Reilly EM; Kelsen D; Trippett TM; Jones DR; Matei IR; Jarnagin WR; Lyden D
Cell; 2020 Aug; 182(4):1044-1061.e18. PubMed ID: 32795414
[TBL] [Abstract][Full Text] [Related]
14. Silence of fibronectin 1 increases cisplatin sensitivity of non-small cell lung cancer cell line.
Gao W; Liu Y; Qin R; Liu D; Feng Q
Biochem Biophys Res Commun; 2016 Jul; 476(1):35-41. PubMed ID: 27207836
[TBL] [Abstract][Full Text] [Related]
15. Versatile Pt NCs-based chemotherapeutic agents significantly induce the apoptosis of cisplatin-resistant non-small cell lung cancer.
Xin Y; Huang X; Li Z; Zhao W; Wang C; Wang S; Yue X; Mo H; Li H
Biochem Biophys Res Commun; 2019 Apr; 512(2):218-223. PubMed ID: 30885437
[TBL] [Abstract][Full Text] [Related]
16. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
17. Chinese herbal medicine Feiyanning cooperates with cisplatin to enhance cytotoxicity to non-small-cell lung cancer by inhibiting protective autophagy.
Zheng Z; Ma Y; Wang L; Deng H; Wang Z; Li J; Xu Z
J Ethnopharmacol; 2021 Aug; 276():114196. PubMed ID: 33984457
[TBL] [Abstract][Full Text] [Related]
18. The PVT1/miR-216b/Beclin-1 regulates cisplatin sensitivity of NSCLC cells via modulating autophagy and apoptosis.
Chen L; Han X; Hu Z; Chen L
Cancer Chemother Pharmacol; 2019 May; 83(5):921-931. PubMed ID: 30859368
[TBL] [Abstract][Full Text] [Related]
19. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3.
Qi MM; Ge F; Chen XJ; Tang C; Ma J
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5242-5250. PubMed ID: 31298375
[TBL] [Abstract][Full Text] [Related]
20. Correlation between membrane proteins and sizes of extracellular vesicles and particles: A potential signature for cancer diagnosis.
Zhai C; Xie F; Xu J; Yang Y; Zheng W; Hu H; Ding X; Yu H
J Extracell Vesicles; 2023 Dec; 12(12):e12391. PubMed ID: 38050829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
